U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H20ClN3O2.ClH.H2O
Molecular Weight 364.267
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZACOPRIDE HYDROCHLORIDE

SMILES

O.Cl.COC1=CC(N)=C(Cl)C=C1C(=O)NC2CN3CCC2CC3

InChI

InChIKey=NPXXKMBXEODDAF-UHFFFAOYSA-N
InChI=1S/C15H20ClN3O2.ClH.H2O/c1-21-14-7-12(17)11(16)6-10(14)15(20)18-13-8-19-4-2-9(13)3-5-19;;/h6-7,9,13H,2-5,8,17H2,1H3,(H,18,20);1H;1H2

HIDE SMILES / InChI

Molecular Formula C15H20ClN3O2
Molecular Weight 309.791
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1514881 | https://www.ncbi.nlm.nih.gov/pubmed/12540230 | https://www.ncbi.nlm.nih.gov/pubmed/24365159 | https://www.ncbi.nlm.nih.gov/pubmed/1312602 | https://www.ncbi.nlm.nih.gov/pubmed/8263156

Zacopride is a potent antagonist at the 5-HT3 receptor and an agonist at the 5-HT4 receptor with antiemetic, anxiolytic and nootropic effects in animal models. Zacopride also has pro-respiratory effects, both reducing sleep apnea and reversing opioid-induced respiratory depression in animal studies. Zacopride has been tested in clinical trials for the treatment of schizophrenia but was found unsuccessful.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.39 nM [Ki]
1.5 nM [Ki]
5.95 null [pEC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[3H]5-hydroxytryptamine labels the agonist high affinity state of the cloned rat 5-HT4 receptor.
1996 May 23
Opposite effects of antidepressants and corticosterone on the sensitivity of hippocampal CA1 neurons to 5-HT1A and 5-HT4 receptor activation.
2001 May
Comparison of the effects of 5-HT1A and 5-HT4 receptor activation on field potentials and epileptiform activity in rat hippocampus.
2002 Dec
Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease.
2004
MD-354 potentiates the antinociceptive effect of clonidine in the mouse tail-flick but not hot-plate assay.
2004 Jul 14
Antinociception: mechanistic studies on the action of MD-354 and clonidine. Part 1. The 5-HT3 component.
2005 Dec 28
5-HT(3) receptors, alcohol and aggressive behavior in mice.
2005 May
Imipramine treatment ameliorates corticosterone-induced alterations in the effects of 5-HT1A and 5-HT4 receptor activation in the CA1 area of rat hippocampus.
2006 Jul
Imipramine and citalopram reverse corticosterone-induced alterations in the effects of the activation of 5-HT(1A) and 5-HT(2) receptors in rat frontal cortex.
2006 Sep
Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro.
2008 Jun 30
5-Hydroxytryptamine Receptor Subtypes and their Modulators with Therapeutic Potentials.
2009 Jun
Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice.
2010 Jul
Reduced signal transduction by 5-HT4 receptors after long-term venlafaxine treatment in rats.
2010 Oct
Patents

Sample Use Guides

0.2, 0.4, 0.8 and 1.6 mg/day for 4 weeks
Route of Administration: Oral
In Vitro Use Guide
Adrenal explants, obtained from patients undergoing expanded nephrectomy for kidney cancer, were immediately transported to the laboratory in Dulbecco Modified Eagle’s Medium (DMBM). After dissection and preincubation in DMEM at 20 C, adrenocortical fragments consisting of both glomerulosa and fasciculata zones were mixed with Bio-Gel P2 and transferred into perifusion chambers. Each perifusion column contained approximately 100 mg wet tissue: The perifusion chambers were supplied with DMEM at a constant flow rate (260 mkL/min). The pH (7.4) and temperature (37 C) were kept constant throughout the experiment. The perifusion medium was continuously gassed with a 95% O2-5% CO2 mixture. The tissues were allowed to stabilize for 2 h before zacopride was administered. Zacopride was dissolved in gassed DMEM and infused for 20 min into the perifusion chambers at the same flow rate as DMEM alone by means of a multichannel peristaltic pump. Fractions of the effluent perifusate were collected every 5 min and immediately frozen until assay. Aldosterone and cortisol concentrations were determined by RIA.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:40:57 GMT 2023
Edited
by admin
on Fri Dec 15 17:40:57 GMT 2023
Record UNII
XL0QQG9B0Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZACOPRIDE HYDROCHLORIDE
MART.   USAN  
USAN  
Official Name English
ZACOPRIDE HYDROCHLORIDE [MART.]
Common Name English
ZACOPRIDE HCL
Common Name English
AHR-11190-B
Code English
ZACOPRIDE HYDROCHLORIDE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28197
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
NCI_THESAURUS C267
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
Code System Code Type Description
MESH
C055971
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
EPA CompTox
DTXSID4045686
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
PUBCHEM
19849157
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
ChEMBL
CHEMBL18041
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
CAS
99617-34-2
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
NCI_THESAURUS
C152943
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
FDA UNII
XL0QQG9B0Y
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
USAN
X-68
Created by admin on Fri Dec 15 17:40:57 GMT 2023 , Edited by admin on Fri Dec 15 17:40:57 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY